Prospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Feb 28, 2021; 27(8): 725-736
Published online Feb 28, 2021. doi: 10.3748/wjg.v27.i8.725
Table 1 Patient and lesion characteristics
Patient characteristics (n = 68)

Sex, n (%)
Male17 (25)
Female51 (75)
Age, median (range)52 ± 10.5 (32-71)
Indication for EFTR, n (%)
Submucosal tumor66 (97.1)
Early cancer2 (2.9)
Location of lesion, n (%)
Cardia5 (7.3)
Gastric fundus41 (60.2)
Gastric body12 (17.6)
Antrum6 (8.8)
Duodenum1 (1.4)
Rectum4 (4.4)
Maximum diameter of lesion, mean, mm (range)20, 12.6 ± 4.3 (3-20)
Table 2 Procedural data (entire cohort)
Median procedure time, min (range)

Total procedure time53.7 ± 41.5 (12-263)
EFTR time39.6 ± 38.0 (5-236)
OTSC defect closure time5.0 ± 3.8 (2-26)
Technical success, n (%)68 (100)
R0 resection, n (%)67 (98.5)
Table 3 Lesion characteristics
Pathological diagnosis, n (%)

GIST42 (61.7)
Leiomyoma14 (20.5)
Schwannoma4 (5.8)
Ectopic pancreas2 (2.9)
Endometriosis1 (1.4)
Fibrolipomatous hyperplasia1 (1.4)
Colorectal adenocarcinoma2 (2.8)
Inflammatory myofibroblastic tumor like hyperplasia1 (1.4)
Hyaline degeneration with calcification1 (1.4)
Table 4 Adverse events
Procedure-related adverse events, n (%)

Mild adverse events1
Abdominal pain18 (26.5)
Discomfort1 (1.4)
Elevated body temperature7 (10.3)
Moderate adverse events2
Bleeding1 (1.5)
Fever8 (11.8)
Local peritonitis2 (2.9)
Severe adverse events30
Perforation0
Persistent peritonitis0